Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Capital Expenditures: 2023-2025

Historic Capital Expenditures for Inhibrx Biosciences (INBX) over the last 1 years, with Sep 2025 value amounting to $10,000.

  • Inhibrx Biosciences' Capital Expenditures fell 95.95% to $10,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $294,000, marking a year-over-year decrease of 95.12%. This contributed to the annual value of $2.6 million for FY2024, which is 43.46% down from last year.
  • As of Q3 2025, Inhibrx Biosciences' Capital Expenditures stood at $10,000, which was down 52.38% from $21,000 recorded in Q1 2025.
  • In the past 5 years, Inhibrx Biosciences' Capital Expenditures ranged from a high of $3.4 million in Q4 2023 and a low of $10,000 during Q3 2025.
  • Moreover, its 3-year median value for Capital Expenditures was $408,000 (2023), whereas its average is $829,875.
  • Data for Inhibrx Biosciences' Capital Expenditures shows a maximum YoY tumbled of 99.54% (in 2024) over the last 5 years.
  • Over the past 3 years, Inhibrx Biosciences' Capital Expenditures (Quarterly) stood at $3.4 million in 2023, then tumbled by 99.54% to $16,000 in 2024, then plummeted by 95.95% to $10,000 in 2025.
  • Its Capital Expenditures was $10,000 in Q3 2025, compared to $21,000 in Q1 2025 and $16,000 in Q4 2024.